2023 Q2 Form 10-Q Financial Statement

#000149315223016481 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $2.106M $2.175M $1.849M
YoY Change 12.69% 17.64% 40.0%
Cost Of Revenue $1.414M $1.261M $1.142M
YoY Change 10.08% 10.38% 29.96%
Gross Profit $691.5K $914.5K $706.8K
YoY Change 18.42% 29.39% 59.97%
Gross Profit Margin 32.84% 42.04% 38.23%
Selling, General & Admin $827.9K $841.9K $668.5K
YoY Change -33.65% 25.94% 11.21%
% of Gross Profit 119.71% 92.06% 94.58%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $16.73K $14.45K $15.89K
YoY Change -5.77% -9.09% -58.12%
% of Gross Profit 2.42% 1.58% 2.25%
Operating Expenses $827.9K $841.9K $668.5K
YoY Change -33.65% 25.94% 11.21%
Operating Profit -$136.3K $72.61K $38.31K
YoY Change -79.46% 89.54% -124.05%
Interest Expense $27.84K $18.96K -$53.47K
YoY Change 42.31% -135.46% -1507.11%
% of Operating Profit 26.11% -139.57%
Other Income/Expense, Net -$9.676K -$181.00 $1.500K
YoY Change -100.7% -112.07% -242.86%
Pretax Income -$146.0K $72.43K $12.51K
YoY Change -120.47% 479.0% -108.5%
Income Tax $5.784K $8.160K $13.57K
% Of Pretax Income 11.27% 108.47%
Net Earnings -$129.2K -$49.41K -$92.66K
YoY Change -142.03% -46.67% -36.93%
Net Earnings / Revenue -6.14% -2.27% -5.01%
Basic Earnings Per Share -$0.01 $0.00 $0.00
Diluted Earnings Per Share -$0.01 $0.00 -$4.043K
COMMON SHARES
Basic Shares Outstanding 22.94M shares 22.94M shares 22.92M shares
Diluted Shares Outstanding 22.94M shares 22.94M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $841.5K $863.0K $592.6K
YoY Change 20.42% 45.63% 4.23%
Cash & Equivalents $836.8K $863.0K $490.7K
Short-Term Investments $4.680K $102.0K
Other Short-Term Assets $74.40K $96.33K $48.72K
YoY Change 16.91% 97.72% -66.2%
Inventory
Prepaid Expenses $74.40K $96.33K
Receivables $646.6K $725.6K $736.9K
Other Receivables $58.16K $87.02K $159.5K
Total Short-Term Assets $1.621M $1.772M $1.538M
YoY Change -42.54% 15.23% 14.89%
LONG-TERM ASSETS
Property, Plant & Equipment $154.3K $132.4K $854.1K
YoY Change 3.34% -84.49% 5.61%
Goodwill $1.426M $1.426M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $341.2K $334.6K $386.0K
YoY Change -14.27% -13.31% -18.79%
Other Assets $3.263M $3.328M $396.7K
YoY Change 2.72% 738.92% 3.97%
Total Long-Term Assets $3.418M $3.460M $3.299M
YoY Change 2.75% 4.88% -3.94%
TOTAL ASSETS
Total Short-Term Assets $1.621M $1.772M $1.538M
Total Long-Term Assets $3.418M $3.460M $3.299M
Total Assets $5.038M $5.232M $4.837M
YoY Change -18.03% 8.17% 1.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $34.81K $27.31K $31.53K
YoY Change -7.31% -13.4% -34.95%
Accrued Expenses $553.9K $541.1K $494.7K
YoY Change -46.45% 9.38% 1.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $30.47K $30.27K $206.2K
YoY Change 3.27% -85.32% 52.49%
Total Short-Term Liabilities $1.007M $901.8K $962.4K
YoY Change -36.64% -6.29% 36.08%
LONG-TERM LIABILITIES
Long-Term Debt $39.11K $46.81K $648.0K
YoY Change -44.3% -92.78% -13.01%
Other Long-Term Liabilities $1.440M $1.451M $1.135M
YoY Change 26.22% 27.88% -0.35%
Total Long-Term Liabilities $2.393M $2.540M $1.783M
YoY Change 34.05% 42.49% -5.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.007M $901.8K $962.4K
Total Long-Term Liabilities $2.393M $2.540M $1.783M
Total Liabilities $3.400M $3.442M $2.715M
YoY Change 0.76% 26.75% 10.96%
SHAREHOLDERS EQUITY
Retained Earnings -$11.52M -$11.39M
YoY Change 8.11%
Common Stock $2.294K $2.294K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.638M $1.790M $2.092M
YoY Change
Total Liabilities & Shareholders Equity $5.038M $5.232M $4.837M
YoY Change -18.03% 8.17% 1.34%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$129.2K -$49.41K -$92.66K
YoY Change -142.03% -46.67% -36.93%
Depreciation, Depletion And Amortization $16.73K $14.45K $15.89K
YoY Change -5.77% -9.09% -58.12%
Cash From Operating Activities $83.33K $71.61K $101.6K
YoY Change -27.97% -29.48% -161.18%
INVESTING ACTIVITIES
Capital Expenditures $38.59K -$5.420K
YoY Change -31.04%
Acquisitions
YoY Change
Other Investing Activities -$4.600K $107.3K -$4.180K
YoY Change -47.9% -2666.99% -88.95%
Cash From Investing Activities -$43.19K $107.3K -$9.600K
YoY Change 389.13% -1217.71% -78.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -66.36K -$105.8K -55.24K
YoY Change 50946.15% 91.61% -136.89%
NET CHANGE
Cash From Operating Activities 83.33K $71.61K 101.6K
Cash From Investing Activities -43.19K $107.3K -9.600K
Cash From Financing Activities -66.36K -$105.8K -55.24K
Net Change In Cash -26.22K $73.06K 36.71K
YoY Change -124.57% 99.02% -159.28%
FREE CASH FLOW
Cash From Operating Activities $83.33K $71.61K $101.6K
Capital Expenditures $38.59K -$5.420K
Free Cash Flow $44.74K $71.61K $107.0K
YoY Change -61.33% -33.06% -167.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001599117
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
usd
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
usd
CY2023Q1 us-gaap Gain Loss On Condemnation
GainLossOnCondemnation
usd
CY2023Q1 MNTR Increase In Accrued Investment Interest Income
IncreaseInAccruedInvestmentInterestIncome
usd
CY2023Q1 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
usd
CY2023Q1 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
usd
CY2023Q1 us-gaap Increase Decrease In Finance Receivables
IncreaseDecreaseInFinanceReceivables
usd
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
CY2022Q1 MNTR Payments To Proceeds From Investment Securities
PaymentsToProceedsFromInvestmentSecurities
usd
CY2023Q1 MNTR Down Payment On Right Of Use Assets
DownPaymentOnRightOfUseAssets
usd
CY2023Q1 MNTR Proceeds From Warrants Converted To Common Stock
ProceedsFromWarrantsConvertedToCommonStock
usd
CY2023Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
CY2023Q1 MNTR Property And Equipment Acquired Via Longterm Debt
PropertyAndEquipmentAcquiredViaLongtermDebt
usd
CY2023Q1 MNTR Investment In Account Receivable Current
InvestmentInAccountReceivableCurrent
usd
CY2022Q4 MNTR Investment In Account Receivable Current
InvestmentInAccountReceivableCurrent
usd
CY2023Q1 MNTR Employee Retention Tax Credits
EmployeeRetentionTaxCredits
usd
CY2022Q4 MNTR Employee Retention Tax Credits
EmployeeRetentionTaxCredits
usd
CY2023Q1 MNTR Employee Retention Tax Credits As Refund
EmployeeRetentionTaxCreditsAsRefund
usd
CY2022Q1 MNTR Employee Retention Tax Credits As Refund
EmployeeRetentionTaxCreditsAsRefund
usd
CY2023Q1 MNTR Operating Lease Cost Included In Cost Of Goods
OperatingLeaseCostIncludedInCostOfGoods
usd
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
usd
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
usd
CY2023Q1 MNTR Property Additions
PropertyAdditions
usd
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
CY2023Q1 us-gaap Gain Loss On Sale Of Property
GainLossOnSaleOfProperty
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-55323
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Mentor Capital, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0395098
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
5964 Campus Court
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Plano
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75093
CY2023Q1 dei City Area Code
CityAreaCode
(760)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
788-4700
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22941357 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
862992 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
789930 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
725570 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
633778 usd
CY2023Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
87021 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
230322 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
96327 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
66000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
1771910 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1720030 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
355725 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
355725 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
223293 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
208847 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
132432 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
146878 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
354964 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
370164 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1212026 usd
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
895323 usd
CY2023Q1 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
204573 usd
CY2022Q4 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
315309 usd
CY2023Q1 us-gaap Deposit Assets
DepositAssets
25575 usd
CY2022Q4 us-gaap Deposit Assets
DepositAssets
25575 usd
CY2023Q1 us-gaap Long Term Investments
LongTermInvestments
104431 usd
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
94431 usd
CY2023Q1 us-gaap Goodwill
Goodwill
1426182 usd
CY2022Q4 us-gaap Goodwill
Goodwill
1426182 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3327751 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3126984 usd
CY2023Q1 us-gaap Assets
Assets
5232093 usd
CY2022Q4 us-gaap Assets
Assets
4993892 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
27305 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
32092 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
541131 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
658743 usd
CY2023Q1 MNTR Economic Injury Disaster Loan Current Portion
EconomicInjuryDisasterLoanCurrentPortion
12895 usd
CY2022Q4 MNTR Economic Injury Disaster Loan Current Portion
EconomicInjuryDisasterLoanCurrentPortion
3191 usd
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
225738 usd
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
232058 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
64484 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
62861 usd
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
30266 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
29011 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
901819 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1017956 usd
CY2023Q1 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
1160446 usd
CY2022Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
1153948 usd
CY2023Q1 MNTR Economic Injury Disaster Loan
EconomicInjuryDisasterLoan
147170 usd
CY2022Q4 MNTR Economic Injury Disaster Loan
EconomicInjuryDisasterLoan
157869 usd
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
894995 usd
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
575852 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
290480 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
307303 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
46811 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
54865 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2539902 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2249837 usd
CY2023Q1 us-gaap Liabilities
Liabilities
3441721 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3267793 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
11 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
11 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
11 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
11 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22941357 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22941357 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22941357 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22941357 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
2294 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2294 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
13085993 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
13085993 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11394877 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11345465 usd
CY2023Q1 MNTR Noncontrolling Interest
NoncontrollingInterest
96962 usd
CY2022Q4 MNTR Noncontrolling Interest
NoncontrollingInterest
-16723 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1790372 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1726099 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5232093 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4993892 usd
CY2023Q1 us-gaap Revenues
Revenues
2175135 usd
CY2022Q1 us-gaap Revenues
Revenues
1848898 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
1260601 usd
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
1149015 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
914534 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
699883 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
841920 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
668507 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
72614 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
31376 usd
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
-42680 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
6660 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
14353 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
18959 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
18207 usd
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
26168 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12118 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1500 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-181 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18866 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
72433 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
12510 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8160 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13570 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
64273 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-1060 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
113685 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
91599 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-49412 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-92659 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.002
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.004
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22941357 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22941357 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2078677 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
14346 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-1060 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2091963 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1726099 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
64273 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1790372 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
64273 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-1060 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14446 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15890 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
95169 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
36656 usd
CY2022Q1 us-gaap Gain Loss On Condemnation
GainLossOnCondemnation
26168 usd
CY2023Q1 MNTR Amortization Of Discount On Investment In Account Receivable
AmortizationOfDiscountOnInvestmentInAccountReceivable
-6564 usd
CY2022Q1 MNTR Amortization Of Discount On Investment In Account Receivable
AmortizationOfDiscountOnInvestmentInAccountReceivable
-13470 usd
CY2022Q1 MNTR Increase In Accrued Investment Interest Income
IncreaseInAccruedInvestmentInterestIncome
-878 usd
CY2022Q1 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-250 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-42430 usd
CY2022Q1 us-gaap Increase Decrease In Finance Receivables
IncreaseDecreaseInFinanceReceivables
-19662 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
91792 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
30447 usd
CY2023Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-143301 usd
CY2022Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-14153 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
32322 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8268 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1995 usd
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1150 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-4787 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-9746 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-118607 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
55830 usd
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1136 usd
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
6498 usd
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
6700 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
71610 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
101548 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5422 usd
CY2023Q1 MNTR Payments To Proceeds From Investment Securities
PaymentsToProceedsFromInvestmentSecurities
10000 usd
CY2022Q1 MNTR Down Payment On Right Of Use Assets
DownPaymentOnRightOfUseAssets
4280 usd
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
117300 usd
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
100 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
107300 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9602 usd
CY2022Q1 MNTR Proceeds From Warrants Converted To Common Stock
ProceedsFromWarrantsConvertedToCommonStock
14346 usd
CY2022Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
21950 usd
CY2023Q1 MNTR Payments On Longterm Debt
PaymentsOnLongtermDebt
6799 usd
CY2022Q1 MNTR Payments On Longterm Debt
PaymentsOnLongtermDebt
5294 usd
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
99049 usd
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
42339 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-105848 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-55237 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
73062 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
36709 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
789930 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
453939 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
862992 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
490648 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
12737 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
11553 usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3568 usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1730 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
411872 usd
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
46760 usd
CY2022Q1 MNTR Property And Equipment Acquired Via Longterm Debt
PropertyAndEquipmentAcquiredViaLongtermDebt
22480 usd
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_800_eus-gaap--NatureOfOperations_zO4cwJtOYx9k" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="catty_007"/>Note 1 - <span id="xdx_82B_z1obumXdjuGl">Nature of operations</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Corporate Structure Overview</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mentor Capital, Inc. (“Mentor” or “the Company”), reincorporated under the laws of the State of <span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20230101__20230331_zScLC7eoovF2" title="Entity incorporation, state or country code">Delaware</span> in September 2015.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The entity was originally founded as an investment partnership in Silicon Valley, California, by the current CEO in 1985 and subsequently incorporated under the laws of the State of California on <span id="xdx_908_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331_zXGW6Kl5eWM2" title="Entity incorporation, date of incorporation">July 29, 1994</span>. On September 12, 1996, the Company’s offering statement was qualified pursuant to Regulation A of the Securities Act, and the Company began to trade its shares publicly. On August 21, 1998, the Company filed for voluntary reorganization, and on January 11, 2000, the Company emerged from Chapter 11 reorganization. The Company relocated to San Diego, California, and contracted to provide financial assistance and investment in small businesses. On May 22, 2015, a corporation named Mentor Capital, Inc. (“Mentor Delaware”) was incorporated under the laws of the State of Delaware. A shareholder-approved merger between Mentor and Mentor Delaware was approved by the California and Delaware Secretaries of State and became effective September 24, 2015, thereby establishing Mentor as a Delaware corporation. In September 2020, Mentor relocated its corporate office from San Diego, California, to Plano, Texas.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s common stock trades publicly under the trading symbol OTCQB: MNTR.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s broad target industry focus includes energy, staffing, facilities operations, and management services with the goal of ensuring increased market opportunities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mentor has a <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WasteConsolidatorsIncMember_zHzssRexj1lg" title="Equity method investment, ownership percentage">51</span>% interest in Waste Consolidators, Inc. (“WCI”). WCI was incorporated in Colorado in 1999 and operates in Arizona and Texas. It is a long-standing investment of the Company since 2003.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mentor’s <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MentorIPLLCMember_zuQlbd3540Xa" title="Equity method investment, ownership percentage">100</span>% owned subsidiaries, Mentor IP, LLC (“MCIP”), Mentor Partner I, LLC, (“Partner I”), Mentor Partner II, LLC (“Partner II”), and TWG, LLC (“TWG”), are headquartered in Plano, Texas.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MCIP holds intellectual property and licensing rights related to one United States and one Canadian patent associated with THC and CBD vape pens. Patent application and national phase maintenance fees were expensed when paid rather than capitalized and therefore, no capitalized assets related to MCIP are recognized on the consolidated financial statements at March 31, 2023 and December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 27, 2021, the Company and Mentor Partner I entered into a Settlement Agreement and Mutual Release with the G Farma Entities and guarantors (“G Farma Settlors”) to resolve and settle all outstanding claims on an unpaid finance lease receivable and notes receivable of balances of $<span id="xdx_90E_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20210827__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember_zs9pvVeyID2h" title="Finance lease receivable">803,399</span> and $<span id="xdx_90C_eus-gaap--NotesReceivableGross_iI_c20210827__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember_zzHCrTPEEYEi" title="Notes receivable">1,045,051</span>, respectively, plus accrued interest (“Settlement Agreement”). On October 12, 2021, the parties filed a Stipulation for Dismissal and Continued Jurisdiction with the Superior Court of California in the County of Marin. The Court ordered that it retain jurisdiction over the parties under Section 664.6 of the California Code of Civil Procedure to enforce the Settlement Agreement until the performance in full of its terms is met.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2022, September 2022, and October 2022, the G Farma Settlors failed to make monthly payments, and failed to cure each default within 10 days’ notice from Company pursuant to the Settlement Agreement. As a result, $<span id="xdx_907_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_iI_c20220831__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zdE0ZAgcn7g3" title="Liability for unpaid claims"><span id="xdx_904_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zpyb5sl0kN12" title="Liability for unpaid claims"><span id="xdx_903_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_iI_c20221031__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_z0JSYwTO88oa" title="Liability for unpaid claims">2,000,000</span></span></span> should be added to the amount payable by the G Farma Settlors in accordance with the terms of the Settlement Agreement. The Company is requesting that the stipulated judgment be entered against the G Farma Settlors for (1) the remaining amount of the $<span id="xdx_904_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_iI_c20220831__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zuSK7XVDPbue" title="Liability for unpaid claims and claims adjustment expense, net"><span id="xdx_90D_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zVDjGaEf1rvi" title="Liability for unpaid claims and claims adjustment expense, net"><span id="xdx_909_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_iI_c20221031__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zz6vzbmG5zYb" title="Liability for unpaid claims and claims adjustment expense, net">500,000</span></span></span> settlement amount which has not yet been paid by the G Farma Settlors plus $<span id="xdx_902_ecustom--LiabilityForAccruedUnpaidInterest_iI_c20220831__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zTsLCOuSL4l3" title="Liability for accrued unpaid interest"><span id="xdx_902_ecustom--LiabilityForAccruedUnpaidInterest_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zwqgQfjuyUrl" title="Liability for accrued unpaid interest"><span id="xdx_904_ecustom--LiabilityForAccruedUnpaidInterest_iI_c20221031__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zxtLKTT62j32" title="Liability for accrued unpaid interest">2,000,000</span></span></span> and all accrued unpaid interest, (2) the Company’s incurred costs, and (3) attorneys’ fees paid by the Company to obtain the judgment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has retained the reserve on collections of the unpaid lease receivable balance due to the long history of uncertain payments from G Farma. Payments from G Farma will be recognized in Other Income as they are received. Recovery payments of $<span id="xdx_90B_eus-gaap--OtherIncome_c20220101__20221231__dei--LegalEntityAxis__custom--GFarmaLabsLimitedMember_zGvE1EStDd2j" title="Other income">3,550</span> and $<span id="xdx_909_eus-gaap--OtherIncome_c20210101__20211231__dei--LegalEntityAxis__custom--GFarmaLabsLimitedMember_zOYxPd96jTSb" title="Other income">2,000</span> were included in other income in the consolidated financial statements for the year ended December 31, 2022 and 2021, respectively. No recovery payments have received since October 11, 2022. We will continue to pursue collection from the G Farma Settlors over time. See Notes 8 and 18.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 - Nature of operations (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 27, 2022, Pueblo West Organics, LLC, a Colorado limited liability company (“Pueblo West”) exercised a lease prepayment option and purchased manufacturing equipment from Partner II for $<span id="xdx_905_eus-gaap--PaymentsToAcquireMachineryAndEquipment_pdp0_c20220926__20220927__dei--LegalEntityAxis__custom--PuebloWestOrganicsLLCMember_zFf6Atj6Tooa" title="Payments to acquire machinery and equipment">245,369</span>. On September 28, 2022 Partner II transferred full title to the equipment to Pueblo West. Originally, Mentor contributed $<span id="xdx_903_eus-gaap--LimitedPartnersContributedCapital_iI_pp0p0_c20180208__dei--LegalEntityAxis__custom--MentorPartnerIILLCMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ManufacturingFacilityMember_zVEbfBBDUnmd" title="Capital contribution">400,000</span> to Partner II to facilitate the purchase of manufacturing equipment to be leased from Partner II by Pueblo West under a Master Equipment Lease Agreement dated February 11, 2018, as amended. On March 12, 2019, Mentor agreed to use Partner II earnings of $<span id="xdx_907_eus-gaap--PaymentsToAcquireMachineryAndEquipment_pp0p0_c20190311__20190312__dei--LegalEntityAxis__custom--MentorPartnerIILLCMember_zJuMPPoOj4jl" title="Payments to acquire machinery and equipment">61,368</span> to facilitate the purchase of additional manufacturing equipment to Pueblo West under a Second Amendment to the lease. See Note 8.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 18, 2022, following the filing of a declaratory relief action, Mentor received $<span id="xdx_905_ecustom--ContractualInterestsInLegalRecoveriess_c20221117__20221118__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zMtYR1T4UMff" title="Contractual interests in legal recoveriess">459,990</span> from Electrum Partners, LLC (“Electrum”) pursuant to a certain November 14, 2022 Settlement Agreement and Mutual Release, following the Company’s October 21, 2022 lawsuit against Electrum and the escrow agent in the County of San Mateo. The Company applied $<span id="xdx_903_ecustom--ContractualInterestsInLegalRecoveries_iI_c20221118__us-gaap--TypeOfArrangementAxis__custom--RecoveryPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember_zJikR5vPiCwf" title="Contractual interests in legal recoveries">196,666</span> to a certain October 30, 2018, Recovery Purchase Agreement, and $<span id="xdx_901_ecustom--ContractualInterestsInLegalRecoveries_iI_c20221118__us-gaap--TypeOfArrangementAxis__custom--CapitalAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember_z5iFZZZxaIb6" title="Contractual interests in legal recoveries">200,000</span> to an October 31, 2018 and January 28, 2019 Capital Agreement. The Company applied the remaining $<span id="xdx_90B_ecustom--ContractualInterestsInLegalRecoveries_iI_c20221118__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember_zYgI7Fqxmrgk" title="Contractual interests in legal recoveries">63,324</span> to its $<span id="xdx_904_ecustom--ContractualInterestEquityInterest_iI_pp0p0_c20190128__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecondSecuredCapitalAgreementMember_zoU2tzErqyn2" title="Contractual interest equity interest">194,028</span> equity interest in Electrum; this resulted in a $<span id="xdx_906_eus-gaap--LossOnSaleOfInvestments_pp0p0_c20221117__20221118__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember_zf991puUyr4i" title="Loss on investment">130,704</span> loss on the Company’s investment in Electrum. See Note 9.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 21, 2018, Mentor paid $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20181201__20181221__dei--LegalEntityAxis__custom--NeuCourtIncMember_z2WiApBp9Bzj" title="Stock issued, value">10,000</span> to purchase <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20181201__20181221__dei--LegalEntityAxis__custom--NeuCourtIncMember_zipWuJqoLuhf" title="Stock issued, shares">500,000</span> shares of NeuCourt, Inc. (“NeuCourt”) common stock, representing approximately<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_c20230101__20230331__dei--LegalEntityAxis__custom--NeuCourtIncMember_zoneLmOPv8He" title="Entity issued and outstanding common stock, percentage"> 6.13</span>% of NeuCourt’s issued and outstanding common stock at March 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1994-07-29
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11394877 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
53692 usd
CY2021 us-gaap Impairment Of Investments
ImpairmentOfInvestments
116430 usd
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
41930 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_zT3i6b3hjQe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zJ1YUcgrFgY">Use of estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of our consolidated financial statements, and the reported amount of revenues and expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 2 - Summary of significant accounting policies (continued)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates relied upon in preparing these consolidated financial statements include revenue recognition, accounts and notes receivable reserves, expected future cash flows used to evaluate the recoverability of long-lived assets, estimated fair values of long-lived assets used to record impairment charges related to investments, goodwill, amortization periods, accrued expenses, and recoverability of the Company’s net deferred tax assets and any related valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Actual results may differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
0 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
0 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
51959 usd
CY2021 us-gaap Impairment Of Investments
ImpairmentOfInvestments
116430 usd
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
41930 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6700000 shares
CY2023Q1 us-gaap Property Plant And Equipment Impairment
PropertyPlantAndEquipmentImpairment
<p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentImpairment_zBWtYQQLoBzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zG8xG3ZUqlUk">Property and equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed on the declining balance method over the estimated useful lives of various classes of property. The estimated lives of the property and equipment are generally as follows: computer equipment, <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_z59weZa35oS1">3</span> to <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zZFEEW0AvaZi">5</span> years; furniture and equipment, <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zKM883Qzy7oh">7</span> years; and vehicles and trailers, <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember__srt--RangeAxis__srt--MinimumMember_zkdosxCX3iof">4</span> to <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember__srt--RangeAxis__srt--MaximumMember_zAzIPj09Oda8" title="Estimated lives of property and equipment">5</span> years. Depreciation on vehicles used by WCI to service its customers is included in cost of goods sold in the consolidated income statements. All other depreciation is included in selling, general and administrative costs in the consolidated income statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenditures for major renewals and improvements are capitalized, while minor replacements, maintenance, and repairs, which do not extend the asset lives, are charged to operations as incurred. Upon sale or disposition, the cost and related accumulated depreciation are removed from the accounts, and any gain or loss is included in operations. The Company continually monitors events and changes in circumstances that could indicate that the carrying balances of its property and equipment may not be recoverable in accordance with the provisions of ASC 360, <i>“Property, Plant, and Equipment.” </i>When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall, or an adverse action or assessment by a regulator. If an impairment indicator exists, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), the Company will write the carrying value down to the fair value in the period identified.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6700000 shares
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2022 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2021 MNTR Impairment Of Investments1
ImpairmentOfInvestments1
-139148 usd
CY2021 us-gaap Gain Loss On Investments
GainLossOnInvestments
22718 usd
CY2022 us-gaap Gain Loss On Investments
GainLossOnInvestments
41930 usd
CY2021 us-gaap Gain Loss On Investments
GainLossOnInvestments
22718 usd
CY2023Q1 MNTR Purchase Obligation Due In Current Year
PurchaseObligationDueInCurrentYear
117000 usd
CY2023Q1 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
117000 usd
CY2023Q1 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
117000 usd
CY2023Q1 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
117000 usd
CY2023Q1 MNTR Investment In Account Receivable Face Value
InvestmentInAccountReceivableFaceValue
286300 usd
CY2022Q4 MNTR Investment In Account Receivable Face Value
InvestmentInAccountReceivableFaceValue
403600 usd
CY2023Q1 MNTR Investment In Account Receivable Unamortized Discount
InvestmentInAccountReceivableUnamortizedDiscount
81727 usd
CY2022Q4 MNTR Investment In Account Receivable Unamortized Discount
InvestmentInAccountReceivableUnamortizedDiscount
88291 usd
CY2023Q1 MNTR Investment In Account Receivable Net
InvestmentInAccountReceivableNet
204573 usd
CY2022Q4 MNTR Investment In Account Receivable Net
InvestmentInAccountReceivableNet
315309 usd
CY2023Q1 MNTR Investment In Account Receivable Noncurrent
InvestmentInAccountReceivableNoncurrent
204573 usd
CY2022Q4 MNTR Investment In Account Receivable Noncurrent
InvestmentInAccountReceivableNoncurrent
315309 usd
CY2023Q1 MNTR Purchase Obligation Due In Current Year
PurchaseObligationDueInCurrentYear
117000 usd
CY2023Q1 MNTR Investment In Accounts Receivable Face Value
InvestmentInAccountsReceivableFaceValue
117000 usd
CY2023Q1 MNTR Investment In Accounts Receivable Face Value
InvestmentInAccountsReceivableFaceValue
100 usd
CY2023Q1 MNTR Investment In Accounts Receivable Face Value
InvestmentInAccountsReceivableFaceValue
100 usd
CY2023Q1 MNTR Investment In Accounts Receivable Face Value
InvestmentInAccountsReceivableFaceValue
100 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
6456 usd
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
13470 usd
CY2023Q1 MNTR Sales Tax Receivable
SalesTaxReceivable
93942 usd
CY2022Q4 MNTR Sales Tax Receivable
SalesTaxReceivable
237243 usd
CY2023Q1 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
6921 usd
CY2022Q4 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
6921 usd
CY2023Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
87021 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
230322 usd
CY2022 MNTR Employee Retention Credits
EmployeeRetentionCredits
1350161 usd
CY2021Q4 MNTR Employee Retention Tax Credits As Refund
EmployeeRetentionTaxCreditsAsRefund
33222 usd
CY2023Q1 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
31335 usd
CY2022Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
31335 usd
CY2023Q1 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
27374 usd
CY2022Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
27374 usd
CY2023Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
297016 usd
CY2022Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
297016 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
355725 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
355725 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
223293 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
208847 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
132432 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
146878 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
14446 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
15890 usd
CY2022Q1 MNTR Operating Lease Cost Included In Cost Of Goods
OperatingLeaseCostIncludedInCostOfGoods
7964 usd
CY2023Q1 MNTR Operating Lease Cost Included In Operating Costs
OperatingLeaseCostIncludedInOperatingCosts
22179 usd
CY2022Q1 MNTR Operating Lease Cost Included In Operating Costs
OperatingLeaseCostIncludedInOperatingCosts
7200 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
22179 usd
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
15164 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
76768 usd
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
47416 usd
CY2023Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
14483 usd
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
6929 usd
CY2023Q1 MNTR Financing Lease Cost
FinancingLeaseCost
91251 usd
CY2022Q1 MNTR Financing Lease Cost
FinancingLeaseCost
54345 usd
CY2023Q1 us-gaap Lease Cost
LeaseCost
113430 usd
CY2022Q1 us-gaap Lease Cost
LeaseCost
69509 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M
CY2023Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M23D
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M17D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060 pure
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060 pure
CY2023Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.069 pure
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.055 pure
CY2023Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1268848 usd
CY2022Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
897849 usd
CY2023Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
148115 usd
CY2022Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
89939 usd
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
1120733 usd
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
807910 usd
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
225738 usd
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
232058 usd
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
894995 usd
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
575852 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
437219 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
428946 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
82255 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
58782 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
354964 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
370164 usd
CY2023Q1 MNTR Operating Lease Liabilities Current
OperatingLeaseLiabilitiesCurrent
64484 usd
CY2022Q4 MNTR Operating Lease Liabilities Current
OperatingLeaseLiabilitiesCurrent
62861 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
290480 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
307303 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
225738 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
64484 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
306365 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
71279 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Due In Rolling Year Two
FinanceLeaseLiabilityPaymentsDueInRollingYearTwo
290463 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
78611 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Due In Rolling Year Three
FinanceLeaseLiabilityPaymentsDueInRollingYearThree
226040 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
86511 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Due In Rolling Year Four
FinanceLeaseLiabilityPaymentsDueInRollingYearFour
72127 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
54077 usd
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
1120733 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
354964 usd
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
225738 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
64484 usd
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
894995 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
290480 usd
CY2022Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable
SalesTypeAndDirectFinancingLeasesLeaseReceivable
0 usd
CY2023Q1 MNTR Long Term Debt One
LongTermDebtOne
17115 usd
CY2022Q4 MNTR Long Term Debt One
LongTermDebtOne
18427 usd
CY2023Q1 MNTR Long Term Debt Two
LongTermDebtTwo
40903 usd
CY2022Q4 MNTR Long Term Debt Two
LongTermDebtTwo
44529 usd
CY2023Q1 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
1998-08-21
CY2023Q1 MNTR Warrant Redemption Price
WarrantRedemptionPrice
0.10
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P15Y3M18D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P15Y6M
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.11
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.11
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
0 usd
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
0 usd
CY2023Q1 MNTR Warrant Redemption Price
WarrantRedemptionPrice
0.10
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
300000 shares
CY2023Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
44748 shares
CY2022 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
44748 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 MNTR Long Term Debt Three
LongTermDebtThree
19059 usd
CY2022Q4 MNTR Long Term Debt Three
LongTermDebtThree
20920 usd
CY2023Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
77077 usd
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
83876 usd
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
30266 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
29011 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
46811 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
54865 usd
CY2023Q1 MNTR Accrued Salaries And Benefits
AccruedSalariesAndBenefits
922276 usd
CY2022Q4 MNTR Accrued Salaries And Benefits
AccruedSalariesAndBenefits
914072 usd
CY2023Q1 MNTR Accrued Retirement And Other Benefits
AccruedRetirementAndOtherBenefits
499823 usd
CY2022Q4 MNTR Accrued Retirement And Other Benefits
AccruedRetirementAndOtherBenefits
501529 usd
CY2023Q1 MNTR Offset By Shareholder Advance
OffsetByShareholderAdvance
-261653 usd
CY2022Q4 MNTR Offset By Shareholder Advance
OffsetByShareholderAdvance
-261653 usd
CY2023Q1 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
1160446 usd
CY2022Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
1153948 usd
CY2023Q1 MNTR Incentive Fee Percentage
IncentiveFeePercentage
0.01 pure
CY2023Q1 us-gaap Capitalization Longterm Debt And Equity
CapitalizationLongtermDebtAndEquity
260000 usd
CY2023Q1 MNTR Market Capitalization Rate
MarketCapitalizationRate
0.005 pure
CY2023Q1 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
1
CY2023Q1 us-gaap Incentive Fee Expense
IncentiveFeeExpense
0 usd
CY2022Q1 us-gaap Incentive Fee Expense
IncentiveFeeExpense
0 usd
CY2023Q1 us-gaap Loss Contingency Lawsuit Filing Date
LossContingencyLawsuitFilingDate
May 28, 2019
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2023Q1 us-gaap Revenues
Revenues
2175135 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
72614 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
6660 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
18959 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14446 usd
CY2023Q1 us-gaap Assets
Assets
5232093 usd
CY2022Q1 us-gaap Revenues
Revenues
1848898 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
31376 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
14353 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
18207 usd
CY2022Q1 MNTR Property Additions
PropertyAdditions
27902 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15890 usd
CY2022Q1 us-gaap Assets
Assets
4836918 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
72614 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
31376 usd
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-42680 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
6660 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
14353 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
18959 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
18207 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Property
GainLossOnSaleOfProperty
26168 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12118 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1500 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
72433 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
12510 usd

Files In Submission

Name View Source Status
mntr-20230331_cal.xml Edgar Link unprocessable
mntr-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001493152-23-016481-index-headers.html Edgar Link pending
0001493152-23-016481-index.html Edgar Link pending
0001493152-23-016481.txt Edgar Link pending
0001493152-23-016481-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
mntr-20230331.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
mntr-20230331_lab.xml Edgar Link unprocessable
mntr-20230331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending